Home » Stocks » LVTX

LAVA Therapeutics N.V. (LVTX)

Stock Price: $11.30 USD 0.05 (0.44%)
Updated Jun 17, 2021 10:38 AM EDT - Market open
Market Cap 282.53M
Revenue (ttm) 4.11M
Net Income (ttm) n/a
Shares Out 25.11M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $11.30
Previous Close $11.25
Change ($) 0.05
Change (%) 0.44%
Day's Open 10.97
Day's Range 11.00 - 11.32
Day's Volume 1,352
52-Week Range 9.76 - 17.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN SEBASTIÁN & BARCELONA, Spain--(BUSINESS WIRE)--Ysios Capital, Spain's largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed it...

3 weeks ago - Business Wire

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

3 weeks ago - GlobeNewsWire

IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023

4 weeks ago - GlobeNewsWire

UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T c...

4 weeks ago - GlobeNewsWire

UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

2 months ago - GlobeNewsWire

UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...

2 months ago - GlobeNewsWire

LAVA Therapeutics, a Dutch Phase 1/2a biotech developing novel bispecific antibodies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

LAVA Therapeutics N.V. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About LVTX

LAVA Therapeutics is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Our approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by our bispecific gamma-delta T cell engagers, or gamma-delta bsTCEs. These cells have the natural ability to distinguish tumor cells from healthy cells. Activat... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 2021
CEO
Stephen Hurly
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
LVTX
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements